Armistice Capital’s BriaCell Therapeutics Warrant expiring 2031 BCTXL Stock Holding History
Bought
Maintained
Sold
Other funds holding BCTXL
WAM
SM
Armistice Capital's BCTXL Position: Q3 2026 in Review
Armistice Capital held its BriaCell Therapeutics Warrant expiring 2031 (BCTXL) position steady in Q3 2026 at 536,600 shares worth $622K. The position accounts for 0.01% of the portfolio, ranked #195.
Armistice Capital first reported a position in BCTXL in Q1 2026 and has held it in 3 quarters since. 11 funds tracked by Wall St. Rank hold BCTXL as of Q3 2026.
- Armistice Capital held 536,600 shares of BriaCell Therapeutics Warrant expiring 2031 worth $622K as of Q3 2026.
- Armistice Capital left its BriaCell Therapeutics Warrant expiring 2031 share count unchanged in Q3 2026.
- BriaCell Therapeutics Warrant expiring 2031 made up 0.01% of Armistice Capital's portfolio in Q3 2026, its #195 holding.
- Armistice Capital first reported a position in BriaCell Therapeutics Warrant expiring 2031 in Q1 2026 and has held it in 3 quarters since.
- 11 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant expiring 2031 as of Q3 2026.
Based on Armistice Capital's 13F filing for Q3 2026, filed 16 Nov 2026.